A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy-Reference-Cited by-同舟云学术

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

Published:2020-11-08 Issue:2 Volume:35 Page:464-475
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Paller A.S.¹,Siegfried E.C.²,Simpson E.L.³,Cork M.J.⁴,Lockshin B.⁵,Kosloski M.P.⁶,Kamal M.A.⁶,Davis J.D.⁶,Sun X.⁶,Pirozzi G.⁷,Graham N.M.H.⁶,Gadkari A.⁶,Eckert L.⁸^ORCID,Ruddy M.⁶,Bansal A.⁶^ORCID

Affiliation:

1. Northwestern University Feinberg School of Medicine Chicago IL USA

2. Saint Louis University and Cardinal Glennon Children's Hospital St. Louis MO USA

3. Oregon Health and Science University Portland OR USA

4. University of Sheffield Sheffield UK

5. Georgetown University Rockville MD USA

6. Regeneron Pharmaceuticals, Inc. Tarrytown NY USA

7. Sanofi Bridgewater NJ USA

8. Sanofi Chilly‐Mazarin France

Funder

Sanofi

Publisher